Conditions: Neoplasms
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 51
Healthy volunteers: no

Brief summary:
This open-label, multi-center study will evaluate the safety and efficacy of Vemurafenib (RO5185426) in participants with metastatic or unresectable papillary thyroid cancer (PTC) positive for the BRAF V600 mutation and resistant to radioactive iodine therapy. Participants will receive vemurafenib 960 milligrams (mg) orally twice daily until progressive disease or unacceptable toxicity occurs.

Detailed description:

Arms:
arm 1: Vemurafenib in participants naive to any prior systemic TKI therapy. arm 2: Vemurafenib in participants previously treated with TKI therapy active against vascular endothelial growth factor receptor 2 (VEGFR).

Interventions: intervention 1: Vemurafenib
Intervention descriptions: intervention 1: Vemurafenib 960 mg orally twice daily.

Protocol document: